← Leaderboards
Ward Peterson
Symberix, Inc.
$3,625,455
Attributed
$3,625,455
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $999.5K · FY2014–23$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$3,625,455 · 4
By mechanism
R44$3,184,749 · 2
R43$440,706 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “In Vivo”
- David Heimbrook · Leidos Biomedical Research, Inc.$371,850,582
- Leonard Freedman · Leidos Biomedical Research, Inc.$304,459,298
- Dennis R. Burton · Scripps Research Institute$212,708,174
- Mark S Klempner · Tufts Medical Center$128,021,180
- Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
- David M. Margolis · University Of Texas Sw Med Ctr/Dallas$98,374,200
Research focus
In VivoDrug KineticsPlasmaEnzymesPharmaceutical PreparationsReportingQuality Of LifeToxicologyMetabolismDiarrheaAcutePreventEvaluationLeadAnalogIn VitroBaseBeta-GlucuronidaseBacteriaGlucuronidesDrug DiscoveryDosePharmacodynamicsEnterobacteriaceae
Grant awards (6)
MTR1: A Dinucleotide Substrate Enhancement and Molecular ByPass Therapy for Thymidine Kinase 2 Deficiency$897,699
R44 · FY2023 · GM · contact PI
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$999,480
R44 · FY2020 · CA · contact PI
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$987,570
R44 · FY2019 · CA · contact PI
Selection and preclinical development of a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes$300,000
R44 · FY2018 · CA · contact PI
Microbiome Targeted Drugs to Improve NSAID Outcomes$215,706
R43 · FY2015 · DK · contact PI
Improving chemotherapy outcomes with proprietary molecules targeting the human mi$225,000
R43 · FY2014 · CA · contact PI